PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Ginkgo Bioworks Holdings, Inc. (DNA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS37611X1000
CUSIP37611X100
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$2.10B
EPS-$0.46
Revenue (TTM)$251.46M
Gross Profit (TTM)$273.49M
EBITDA (TTM)-$662.28M
Year Range$0.74 - $2.55
Target Price$1.92
Short %21.78%
Short Ratio12.74

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Ginkgo Bioworks Holdings, Inc.

Popular comparisons: DNA vs. PLTR, DNA vs. ARDX, DNA vs. VOO, DNA vs. SPY, DNA vs. VTI, DNA vs. POWW, DNA vs. WBA, DNA vs. INVZ, DNA vs. VIR, DNA vs. MRNA

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Ginkgo Bioworks Holdings, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%December2024FebruaryMarchAprilMay
-92.48%
25.45%
DNA (Ginkgo Bioworks Holdings, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Ginkgo Bioworks Holdings, Inc. had a return of -54.98% year-to-date (YTD) and -42.79% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-54.98%9.49%
1 month-32.06%1.20%
6 months-40.55%18.29%
1 year-42.79%26.44%
5 years (annualized)N/A12.64%
10 years (annualized)N/A10.67%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-28.40%25.62%-23.68%-23.18%
2023-24.31%-5.84%31.01%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of DNA is 23, indicating that it is in the bottom 23% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of DNA is 2323
DNA (Ginkgo Bioworks Holdings, Inc.)
The Sharpe Ratio Rank of DNA is 2323Sharpe Ratio Rank
The Sortino Ratio Rank of DNA is 2727Sortino Ratio Rank
The Omega Ratio Rank of DNA is 2828Omega Ratio Rank
The Calmar Ratio Rank of DNA is 1919Calmar Ratio Rank
The Martin Ratio Rank of DNA is 1919Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


DNA
Sharpe ratio
The chart of Sharpe ratio for DNA, currently valued at -0.47, compared to the broader market-2.00-1.000.001.002.003.00-0.47
Sortino ratio
The chart of Sortino ratio for DNA, currently valued at -0.22, compared to the broader market-4.00-2.000.002.004.006.00-0.22
Omega ratio
The chart of Omega ratio for DNA, currently valued at 0.98, compared to the broader market0.501.001.502.000.98
Calmar ratio
The chart of Calmar ratio for DNA, currently valued at -0.46, compared to the broader market0.002.004.006.00-0.46
Martin ratio
The chart of Martin ratio for DNA, currently valued at -1.10, compared to the broader market-10.000.0010.0020.0030.00-1.10
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.27, compared to the broader market-2.00-1.000.001.002.003.002.27
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.22, compared to the broader market-4.00-2.000.002.004.006.003.22
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.39, compared to the broader market0.501.001.502.001.39
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.83, compared to the broader market0.002.004.006.001.83
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.69, compared to the broader market-10.000.0010.0020.0030.008.69

Sharpe Ratio

The current Ginkgo Bioworks Holdings, Inc. Sharpe ratio is -0.47. This value is calculated based on the past 12 months of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Ginkgo Bioworks Holdings, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2024FebruaryMarchAprilMay
-0.47
2.27
DNA (Ginkgo Bioworks Holdings, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Ginkgo Bioworks Holdings, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-94.90%
-0.60%
DNA (Ginkgo Bioworks Holdings, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Ginkgo Bioworks Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ginkgo Bioworks Holdings, Inc. was 94.90%, occurring on May 10, 2024. The portfolio has not yet recovered.

The current Ginkgo Bioworks Holdings, Inc. drawdown is 94.90%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-94.9%Nov 10, 2021628May 10, 2024
-28.69%Sep 28, 202110Oct 11, 20216Oct 19, 202116
-11.76%Apr 26, 202198Sep 13, 20213Sep 16, 2021101
-11.28%Oct 20, 20213Oct 22, 202111Nov 8, 202114
-8.78%Sep 20, 20211Sep 20, 20213Sep 23, 20214

Volatility

Volatility Chart

The current Ginkgo Bioworks Holdings, Inc. volatility is 35.51%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%December2024FebruaryMarchAprilMay
35.51%
3.93%
DNA (Ginkgo Bioworks Holdings, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Ginkgo Bioworks Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items